Hypothesis

We hypothesize that the CDKN2A/B locus does not merely regulate cell‑cycle arrest but actively directs the fate of misfolded proteins through a yin‑yang mechanism: p16INK4a‑induced ROS promotes the sequestration of toxic oligomers into protective cytoplasmic aggregates (aggresomes/JUNQ/IPOD), whereas p19ARF antagonizes this process by enhancing autophagic‑lysosomal clearance. In Alzheimer’s disease, epigenetic silencing of the locus disrupts this balance, abolishing the containment pathway and allowing soluble toxic species to accumulate.

Mechanistic Model

• p16INK4a arm – Oxidative stress activates ERK1/2/p38 MAPK, raising p16INK4a expression (2). p16INK4a then triggers a ROS‑PKCδ‑dependent block on cytokinesis (4), sustaining ROS production. Elevated ROS oxidizes cytosolic proteins, promoting their misfolding. p16INK4a‑high cells simultaneously upregulate chaperones and scaffold proteins (e.g., CAV1, LMNB1) that remodel membranous compartments (5), creating a permissive environment for the formation of insoluble, ordered aggregates that sequester misfolded species and reduce their diffusible toxicity.
• p19ARF arm – Transcription from the same locus yields p19ARF, which stabilizes p53 and stimulates transcription of autophagy genes (e.g., LC3, Beclin‑1). p19ARF‑driven autophagy accelerates the delivery of sequestered aggregates to lysosomes for degradation, preventing chronic accumulation.
• Dynamic balance – The ratio of p16INK4a to p19ARF determines whether the cell leans toward aggregation‑based containment or clearance‑based resolution. When p16INK4a dominates, aggregates form as a protective depot; when p19ARF dominates, aggregates are rapidly turned over.

Testable Predictions

1. Increasing p16INK4a (via inducible overexpression) in stressed neurons will raise intracellular ROS, increase the number of ubiquitin‑positive/JUNQ‑like inclusions, and reduce soluble oligomeric Aβ/tau levels without increasing cell death.
2. Knock‑down of p19ARF will exacerbate aggregate formation under p16INK4a‑high conditions, whereas p19ARF overexpression will accelerate aggregate clearance and lower inclusion burden.
3. In AD‑model iPSC‑derived neurons, CRISPR‑mediated demethylation of the CDKN2A/B promoter will restore both p16INK4a and p19ARF expression, re‑establish the aggregation‑clearance balance, and rescue synaptic function.
4. Pharmacological inhibition of ROS (e.g., with NAC) will block p16INK4a‑dependent aggregate formation, leading to a rise in soluble toxic species despite low p16INK4a levels.

Experimental Approach

• Cell models: Human iPSC‑derived cortical neurons and astrocytes; inducible p16INK4a and p19ARF constructs; CRISPR‑epigenetic editing tools.
• Readouts: ROS quantification (DCFDA), filter‑trap assay for insoluble aggregates, immunofluorescence for p62/JUNQ/IPOD markers, soluble oligomer ELISA (Aβ42, p‑tau), autophagy flux (LC3‑II/I, p62 turnover), viability assays (LDH, caspase‑3/7).
• Interventions: Tunicamycin or Aβ oligomers to induce proteostatic stress; ROS scavengers; autophagy modulators (bafilomycin A1, rapamycin).
• Analysis: Correlate p16INK4a/p19ARF protein ratios (Western blot) with aggregate load and soluble toxin levels across conditions; use linear mixed models to test interaction effects.

If the data show that p16INK4a‑driven ROS increases protective inclusions while p19ARF promotes their clearance, and that AD‑associated promoter silencing uncouples this relationship, the hypothesis will be supported. Conversely, if p16INK4a elevation fails to generate inclusions or increases toxicity irrespective of p19ARF levels, the model will be falsified.